Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Crizotinib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 42 Lymphoid 11 Plasma cell 7 CNS 6 Gastrointestinal 5 Tumor-Agnostic 4 Genitourinary 4 Other hematologic neoplasm 2 Dermatologic 2 Sarcoma 1 Other solid neoplasm 1 Gynecologic 1 Endocrine 1 Breast 1

Conditions

Neoplasm Metastasis 1 Breast Neoplasms 1

Interventions

Trastuzumab 575 Paclitaxel 555 Cyclophosphamide 532 Docetaxel 473 Capecitabine 404 Letrozole 334 Carboplatin 312 Fulvestrant 307 Doxorubicin 275 Tamoxifen 238 pembrolizumab 220 Anastrozole 204 Epirubicin 201 exemestane 193 Radiotherapy 186 Bevacizumab 182 pertuzumab 177 Gemcitabine 169 Vinorelbine 161 Lapatinib 153 palbociclib 141 130-nm albumin-bound paclitaxel 136 Magnetic Resonance Spectroscopy 130 Albumin-Bound Paclitaxel 128 eribulin 122 Exercise 119 Fluorouracil 109 Taxes 104 Everolimus 96 Cisplatin 96

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02074878 2017-08-09

CRIZENT

Baylor Breast Care Center

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡